Brief: RenovoRx to Present Preclinical Data For Its Platform's Potential Utility for Bile Duct Cancer Treatment
19/05/2022 14:45
May 19 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX TO PRESENT PRECLINICAL RESEARCH DATA
DEMONSTRATING ITS
INNOVATIVE THERAPY PLATFORM’S POTENTIAL UTILITY FOR THE
TREATMENT OF BILE DUCT CANCER
Source text for Eikon: ID:nBwbBLr16a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer